Table 3.
Comparison of baseline data of pathological features in the training set, testing set and validation set (%)
| Features | Training set (n = 78) | Testing set (n = 32) | Validation set (n = 33) | P | |
|---|---|---|---|---|---|
| MVI | Yes | 36(46.15) | 10(31.25) | 18(54.55) | 0.157 |
| No | 42(53.85) | 22(68.75) | 15(45.45) | ||
| Hepatocyte | Positive | 57(73.08) | 28(87.5) | 16(48.48) | 0.002* |
| Negative | 21(26.92) | 4(12.5) | 17(51.52) | ||
| Glypican3 | Negative | 15(19.23) | 9(28.13) | 9(27.27) | 0.488 |
| Positive | 63(80.77) | 23(71.88) | 24(72.73) | ||
| CD34 | Positive | 69(88.46) | 30(93.75) | 25(75.76) | 0.101 |
| Negative | 9(11.54) | 2(6.25) | 8(24.24) | ||
| CK19 | Positive | 73(93.59) | 31(96.88) | 29(87.88) | 0.409 |
| Negative | 5(6.41) | 1(3.13) | 4(12.12) | ||
| Ki67 | > 20% | 58(74.36) | 20(62.5) | 24(72.73) | 0.449 |
| ≤ 20% | 20(25.64) | 12(37.5) | 9(27.27) |
MVI Microvascular invasion
*represents P < 0.05